ecancermedicalscience

Conference Report

Aspirin for the next generation

2 Apr 2013
Nick Henderson, Tom Smith

First used as an analgesic and antipyretic, investigations into aspirin’s anti-inflammatory effects led to its establishment in 1974 as a drug that altered the activity of platelets to influence the course and incidence of myocardial infarction and cerebrovascular disease. It became the standard in treatment and prevention of vascular disorders.

The 25th International Scientific Meeting on aspirin held at the Royal College of Physicians in London on 24th October 2012 took aspirin into fresh fields, among them cancer, diabetes, dementia and gynaecology.

Related Articles

Alfred Jatho, Sheba Nakacubo Gitta, Vincent K Kalungi, Ronald Opito, Samuel Okello, Robinah Komuhendo, James Kafeero, Noleb Mugisha
Hugo Castro-Salguero, Bremilin Ramírez-Najarro, Jorge Tello-Mérida, Lourdes Castro-Salazar, Luis García-Aceituno
Daniel F Pilco-Janeta, Myriam De la Cruz-Puebla, Daisy Guamán-Pilco, Diego Montenegro, Philipp Novotny, William Miranda
Eniola R Kadir, Kikelomo T Adesina, Olatunde Oyebanjo K Ibrahim, Beatrice O Owolabi, Olaniyi O Fatai, Tomilola M Olaseinde, Azeezat D Yakub, Hafsat A Ameen, Suleiman O Agodirin, Adegboyega A Fawole
Roberta Monteiro Batista Sarmento, José Roberto Lapa e Silva, Gustavo Arantes Rosa Maciel, Claudia Ferrer, José Bines